Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.


Player Avatar bwerthrx (84.91) Submitted: 12/5/2012 8:02:49 AM : Outperform Start Price: $8.65 ARNA Score: -75.05

New obesity drug with a novel mechanism of action will likely be much safer than stimulant alternatives which carry a high potential for cardiovascular events and abuse. This drug, which is not a controlled substance, stands to make this company a lot of money considering the obesity/diabetes epidemic in this country. Given this, I also anticipate eventual coverage by most major third party payers which will in turn increase the number of prescriptions for Belviq (lorcaserin)

Featured Broker Partners